Guidelines for definition and diagnosis of severe pulmonary tuberculosis in adults in China (2023)_Chinese Journal of Evidence-Based Medicine

Authors：

 Tuberculosis Professional Committee of Chinese Research Hospital Association , National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen Clinical Research Center for Tuberculosis

Corresponding?author：

Tuberculosis Professional Committee of Chinese Research Hospital Association, Email: blueske_520@163.com

Keywords：

Severe pulmonary tuberculosis; Definition; Standard of diagnosis; Guideline

DOI：

10.7507/1672-2531.202409195

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The significant increase in mortality after tuberculosis (TB) progression to severe disease is a major obstacle to achieving the goal of ending the TB epidemic by 2035. Up to now, there is no clear definition and diagnostic criteria for adult severe tuberculosis at home or abroad, which has a significant adverse impact on the early diagnosis and timely treatment of patients with severe tuberculosis. In order to improve the treatment level of patients with severe pulmonary tuberculosis, reduce mortality and improve prognosis. The Professional Committee of Tuberculosis Science of the Chinese Society of Research Hospitals and Shenzhen Third People's Hospital/National Clinical Medical Research Center of Infectious Diseases/Shenzhen Tuberculosis Clinical Medical Research Center led the formulation of "Guidelines for definition and diagnosis of severe pulmonary tuberculosis in adults in China (2023)", aiming to guide and standardize the definition and diagnosis of severe tuberculosis. So as to improve the level of diagnosis and treatment of severe pulmonary tuberculosis in our country, to maximize the benefit of patients.

Citation： Tuberculosis Professional Committee of Chinese Research Hospital Association, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen Clinical Research Center for Tuberculosis. Guidelines for definition and diagnosis of severe pulmonary tuberculosis in adults in China (2023). Chinese Journal of Evidence-Based Medicine, 2024, 24(12): 1365-1375. doi: 10.7507/1672-2531.202409195 Copy

1.	WHO. Global tuberculosis report 2023. 2023.
2.	毛敏杰, 汪彩紅, 潘蕾. 細胞免疫和體液免疫功能檢測對重癥結核病患者的臨床意義. 中華危重癥醫學雜志(電子版), 2015, 8(2): 109-111.
3.	Duro RP, Figueiredo Dias P, Ferreira AA, et al. Severe tuberculosis requiring intensive care: a descriptive analysis. Crit Care Res Pract, 2017, 2017: 9535463.
4.	劉同倫. 實用結核病學. 沈陽: 遼寧科學技術出版社, 1987: 284-289.
5.	蘇瑾文. 重癥肺結核學免疫特性研究. 北京: 中國人民解放軍醫學院, 2015.
6.	Kim CW, Kim SH, Lee SN, et al. Risk factors related with mortality in patient with pulmonary tuberculosis. Tuberc Respir Dis (Seoul), 2012, 73(1): 38-47.
7.	Loh WJ, Yu Y, Loo CM, et al. Factors associated with mortality among patients with active pulmonary tuberculosis requiring intensive care. Singapore Med J, 2017, 58(11): 656-659.
8.	WHO. WHO handbook for guideline development (2nd ed). Vienna: World Health Organization, 2014.
9.	Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting and evaluation in health care. CMAJ, 2010, 182(18): 839-842.
10.	Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
11.	Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
12.	Higgins JP, Altman DG, G?tzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
13.	Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536.
14.	Wells GA, Shea BJ, O'Connell D, et al. The Newcastle‐Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta‐analyses. 2011.
15.	Moga C, Guo B, Schopflocher D, et al. Development of a quality appraisal tool for case series studies using a modified Delphi technique. 2012.
16.	OCEBM Levels of Evidence Working Group. OCEBM levels of evidence. 2009.
17.	李純. 分析重癥肺結核合并呼吸衰竭的臨床特征. 中國醫藥指南, 2019, 17(24): 51.
18.	劉麗, 閆佩英. 重癥肺結核合并呼吸衰竭的臨床治療體會. 世界最新醫學信息文摘(連續型電子期刊), 2019, 19(38): 89-90.
19.	劉國波. 重癥肺結核合并呼吸衰竭的臨床護理. 中國醫藥指南, 2019, 17(1): 183-184.
20.	劉曉寧, 李曄. 青年重癥肺結核的臨床特點及其影響因素分析. 臨床肺科雜志, 2020, 25(9): 1419-1423.
21.	劉丹. 重癥肺結核合并呼吸衰竭的臨床護理. 飲食科學, 2017, (20): 1.
22.	蘇瑾文, 劉艷華, 楊秉芬, 等. 重癥繼發性肺結核患者差異表達基因和IL-1β表達的驗證. 中華臨床醫師雜志(電子版), 2014, (23): 4186-4190.
23.	蘇瑾文, 劉艷華, 楊秉芬, 等. CCL3、CCL4下調表達和重癥繼發性肺結核病理損傷的關系. 山西醫科大學學報, 2015, 46(4): 300-304.
24.	王譯, 陸利歡, 陳建. 重癥活動性肺結核患者凝血功能變化的臨床分析. 臨床醫藥文獻電子雜志, 2020, 7(13): 27-28.
25.	魯進, 黃漢平. 重癥肺結核病合并類白血病反應誤診分析報告1例. 中國醫藥科學, 2017, 7(18): 254-256.
26.	唐理斌, 李海雯. 經鼻高流量氧療與無創機械通氣在重癥肺結核合并呼吸衰竭中的療效對比研究. 健康必讀, 2019, (33): 23.
27.	戚世欽, 楊榮, 吳春玲. 含卷曲霉素化療方案聯合胸腺五肽和復方氨基酸雙肽治療重癥肺結核的臨床療效分析. 現代診斷與治療, 2016, 27(8): 1431-1433.
28.	國家衛生和計劃生育委員會. 肺結核診斷標準(WS 288-2017). 2017.
29.	WHO. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: module 1: prevention. 2020.
30.	蔡靜, 汪求真, 韓秀霞, 等. 肺結核患者就診臨床表現及變化特點調查分析. 中華疾病控制雜志, 2012, 16(5): 417-420.
31.	李文君, 王玲, 曾令玉, 等. 72例涂陽肺結核患者臨床特點分析. 新疆醫學, 2018, 48(1): 47-50.
32.	張力英, 李琦, 王蘋, 等. 慢性阻塞性肺疾病合并肺性腦病的臨床特征及其危險因素分析. 中華肺部疾病雜志(電子版), 2021, 14(4): 530-532.
33.	中華醫學會呼吸病學分會. 中國成人社區獲得性肺炎診斷和治療指南(2016年版). 中華結核和呼吸雜志, 2016, 39(4): 253-279.
34.	張虹. 優質護理用于重癥結核合并糖尿病的臨床護理效果分析. 糖尿病新世界, 2018, 21(21): 131-132.
35.	陳娟, 毛毅, 陳洪德. 30例危重癥肺結核孕產婦的臨床特征及預后分析. 中國防癆雜志, 2020, 42(6): 638-640.
36.	劉燕俠. 肺結核合并肝性腦病34例護理體會. 中國實用神經疾病雜志, 2015, 18(13): 122.
37.	張亞敬, 姜影, 孫浩, 等. 154例老年肺結核患者的發現與治療轉歸情況分析. 結核與肺部疾病雜志, 2023, 4(1): 48-53.
38.	朱麗雅. 重癥肺結核合并呼吸衰竭的護理. 中國基層醫藥, 2013, 20(2): 296-297.
39.	謝朝云, 覃家露, 熊蕓, 等. 重癥肺結核患者死亡危險因素分析. 人民軍醫, 2018, 61(1): 30-33, 37.
40.	冀小波, 毛敏杰, 徐節坤, 等. 重癥肺結核合并真菌感染患者的臨床特征及發病危險因素分析. 浙江醫學, 2021, 43(18): 2013-2016, 2019.
41.	中華醫學會結核病學分會重癥專業委員會. 結核病營養治療專家共識. 中華結核和呼吸雜志, 2020, 43(1): 17-26.
42.	張楠, 李琦, 潘麗萍, 等. 結核重癥監護室真菌感染的危險因素分析. 中國醫藥導報, 2019, 16(1): 74-76, 81.
43.	王紅巖, 張昕. 結核重癥監護室呼吸機相關性肺炎感染的危險因素分析. 中國醫藥指南, 2020, 18(6): 108-109.
44.	王紅巖, 張昕. 重癥肺結核合并呼吸衰竭的臨床特征分析. 中國醫藥指南, 2020, 18(16): 130-131.
45.	萬青梅. 重癥肺結核合并呼吸衰竭患者的臨床護理方法以及效果評價. 醫學美學美容(中旬刊), 2014, 23(8): 366.
46.	疏欣楊, 唐亮, 孫兵. 呼吸重癥監護病房中以呼吸衰竭為突出表現的肺結核臨床特點. 中日友好醫院學報, 2014, 28(3): 139-142, 封2.
47.	石麗彩, 楊桂梅. 重癥肺結核合并呼吸衰竭患者的護理. 臨床合理用藥雜志, 2012, 5(29): 166.
48.	馬增光, 李志軍, 陳杰勇. 重癥肺結核79例臨床分析. 臨床合理用藥雜志, 2014, 7(25): 39.
49.	李先鋒. 青年重癥肺結核60例觀察與治療. 醫藥前沿, 2014, (8): 115-116.
50.	李紅. 重癥肺結核合并呼吸衰竭臨床分析. 中國衛生標準管理, 2015, 6(12): 132-133.
51.	李海濤, 郭曉新. 初治重癥肺結核發現延遲相關因素分析. 河南預防醫學雜志, 2012, 23(4): 275-276.
52.	龔惠莉. 60例重癥肺結核合并呼吸衰竭臨床分析. 現代預防醫學, 2012, 39(1): 248-249.
53.	劉巖, 丁龍. 30例重癥肺結核回顧性影像分析. 健康必讀旬刊, 2013, 12(11): 101.
54.	Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med, 1995, 23(10): 1638-1652.
55.	中華醫學會結核病學分會. 肺結核診斷和治療指南. 中國實用鄉村醫生雜志, 2013, 20(2): 7-11.
56.	Telisinghe L, Fielding KL, Malden JL, et al. High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. PLoS One, 2014, 9(1): e87262.
57.	Nguyen TBP, Nguyen TA, Luu BK, et al. A comparison of digital chest radiography and Xpert? MTB/RIF in active case finding for tuberculosis. Int J Tuberc Lung Dis, 2020, 24(9): 934-940.
58.	中華醫學會放射學分會傳染病放射學專業委員會. 肺結核影像學及分級診斷專家共識. 新發傳染病電子雜志, 2018, 3(2): 118-127.
59.	劉長春, 古海爾, 常銀勇, 等. 重癥肺結核CT影像分析. 臨床肺科雜志, 2007, 12(12): 1302-1304.
60.	陳影. 老年肺結核臨床分析. 中國實用醫藥, 2015, (15): 61-62.
61.	周偉劍. 艾滋病患者合并重癥肺結核的X線表現的探討. 現代醫用影像學, 2015, 24(6): 902-904.
62.	李寧, 王曉靜, 馮光, 等. 高能量營養乳劑的腸內營養對重癥肺結核機械通氣患者的臨床療效. 臨床肺科雜志, 2013, 18(5): 780-782.
63.	Shaarawy H, El-Sayed Mohamed E. Assessment of the prevalence of pulmonary embolism in patients with severe pulmonary tuberculosis. Egypt J Chest Dis Tuberc, 2018, 67(1): 62-67.
64.	中華人民共和國國家衛生和計劃生育委員會. 結核病分類(WS196—2017). 新發傳染病電子雜志, 2018, 3(3): 191-192.
65.	Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis, 2015, 211(Suppl 2): S21-S28.
66.	《中國防癆雜志》編輯委員會, 中國醫療保健國際交流促進會結核病防治分會基礎學組和臨床學組. 結核分枝桿菌耐藥性檢測專家共識. 中國防癆雜志, 2019, 41(2): 129-137.
67.	中華醫學會結核病學分會臨床檢驗專業委員會. 結核病病原學分子診斷專家共識. 中華結核和呼吸雜志, 2018, 41(9): 688-695.
68.	劉一典. 復治肺結核病診斷和治療專家共識. 中國防癆雜志, 2021, 43(12): 1226-1238.
69.	Fusani L, Tersigni C, Chiappini E, et al. Old biomarkers in tuberculosis management: are they still useful. A systematic review. Expert Rev Anti Infect Ther, 2021, 19(10): 1191-1203.
70.	Pierce R, Bigham MT, Giuliano JS. Use of procalcitonin for the prediction and treatment of acute bacterial infection in children. Curr Opin Pediatr, 2014, 26(3): 292-298.
71.	Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis, 2020, 70(3): 538-542.
72.	Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J, 2023, 61(4): 2200735.
73.	Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med, 2008, 177(5): 498-505.
74.	李成行, 李月翠. 檢測內毒素與C反應蛋白在診斷肺結核合并革蘭陰性菌感染中的意義. 中國防癆雜志, 2013, 35(9): 702-705.
75.	萬學紅, 盧雪峰. 診斷學(第9版). 北京: 人民衛生出版社, 2018: 409-442.
76.	Jones BE, Oo MM, Taikwel EK, et al. CD4 cell counts in human immunodeficiency virus-negative patients with tuberculosis. Clin Infect Dis, 1997, 24(5): 988-991.
77.	俞朝賢, 李德憲, 王娟, 等. 結核重癥監護室患者外周血CD4+T淋巴細胞的檢測與臨床意義. 現代醫院, 2019, 19(7): 1084-1086.
78.	汪彩紅, 邱君克, 黃曉慶, 等. 重癥肺結核患者外周血T細胞亞群在預后不良患者中的表達及臨床意義. 中華醫院感染學雜志, 2020, 30(9): 1327-1330.
79.	衛芳征. 外周血T細胞亞群和紅細胞免疫功能與重癥肺結核患者不良預后的相關性. 臨床肺科雜志, 2018, 23(9): 1561-1565.
80.	黃健, 李明瑛, 牛文一, 等. 外周血Blimp1、IFN-γ、IL-10水平與重癥肺結核的相關性分析. 分子診斷與治療雜志, 2020, 12(12): 1745-1748.
81.	章敏. 外周血IFN-γ、IL-10水平及紅細胞免疫功能對重癥肺結核患者死亡預后的預測價值. 標記免疫分析與臨床, 2020, 27(7): 1161-1165.
82.	Kho ME, McDonald E, Stratford PW, et al. Interrater reliability of APACHE Ⅱ scores for medical surgical intensive care patients: a prospect blinded study. Am J Crit Care, 2007, 16: 378-380.
83.	Lambden S, Laterre PF, Levy MM, et al. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care, 2019, 23(1): 374.
84.	王超, 蘇強, 張淑文, 等. 多器官功能障礙綜合征病情嚴重度評分系統. 中國醫學科學院學報, 2007, 29(4): 497-500.
85.	Wang D, Willis DR, Yih Y. The pneumonia severity index: assessment and comparison to popular machine learning classifiers. Int J Med Inform, 2022, 163: 104778.
86.	李寧, 王曉靜, 馮光, 等. 重癥肺結核合并COPD患者機械通氣死亡預后因素分析. 臨床肺科雜志, 2013, 18(4): 711-712.
87.	Tatar D, Senol G, Kirakli C, et al. Contributing factors to mortality rates of pulmonary tuberculosis in intensive care units. J Chin Med Assoc, 2018, 81(7): 605-610.
88.	Galvin J, Tiberi S, Akkerman O, et al. Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. Pulmonology, 2022, 28(4): 297-309.
89.	Rollas K, Kara A, Orta? Ersoy NE, et al. Acute tuberculosis in the intensive care unit. Turk J Med Sci, 2015, 45(4): 882-887.
90.	張如云, 張靜, 雷軒. 血清白蛋白、SOFA評分及APACHEⅡ評分對重癥肺結核患者預后的評估價值. 臨床肺科雜志, 2023, 28(3): 399-401,411.
91.	Kim S, Kim H, Kim WJ, et al. Mortality and predictors in pulmonary tuberculosis with respiratory failure requiring mechanical ventilation. Int J Tuberc Lung Dis, 2016, 20(4): 524-529.
92.	Cegielski JP, Arab L, Cornoni-Huntley J. Nutritional risk factors for tuberculosis among adults in the United States, 1971-1992. Am J Epidemiol, 2012, 176(5): 409-422.
93.	WHO. WHO guidelines approved by the guidelines review committee. 2013.
94.	Mueller C, Compher C, Ellen DM, et al. A. S. P. E. N. clinical guidelines: nutrition screening, assessment, and intervention in adults. JPEN J Parenter Enteral Nutr, 2011, 35(1): 16-24.
95.	Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr, 2003, 22(3): 321-336.
96.	Heyland DK, Dhaliwal R, Jiang X, et al. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. Crit Care, 2011, 15(6): R268.
97.	章志俊, 譚守勇. 營養風險篩查在結核病治療中應用. 中國防癆雜志, 2015, 37(9): 971-974.
98.	營養風險及營養支持調查協作組, 蔣朱明, 陳偉, 等. 中國東、中、西部大城市三甲醫院營養不良(不足)、營養風險發生率及營養支持應用狀況調查. 中國臨床營養雜志, 2008, 16(6): 335-337.
99.	顧良軍, 詹斯·康卓普, 雷米·梅耶, 等. 營養風險篩查2002改善臨床結局. 中華臨床營養雜志, 2013, 21(3): 133-139.
100.	Felder S, Lechtenboehmer C, Bally M, et al. Association of nutritional risk and adverse medical outcomes across different medical inpatient populations. Nutrition, 2015, 31(11-12): 1385-1393.
101.	Mukhopadhyay A, Henry J, Ong V, et al. Association of modified NUTRIC score with 28-day mortality in critically ill patients. Clin Nutr, 2017, 36(4): 1143-1148.
102.	Canales C, Elsayes A, Yeh DD, et al. Nutrition risk in critically ill versus the nutritional risk screening 2002: are they comparable for assessing risk of malnutrition in critically ill patients. JPEN J Parenter Enteral Nutr, 2019, 43(1): 81-87.
103.	Heyland DK, Dhaliwal R, Wang M, et al. The prevalence of iatrogenic underfeeding in the nutritionally 'at-risk' critically ill patient: results of an international, multicenter, prospective study. Clin Nutr, 2015, 34(4): 659-666.
104.	陳志, 梁建琴. 結核病重癥患者營養評估及營養支持治療專家共識. 中國防癆雜志, 2022, 44(5): 421-432.

1. WHO. Global tuberculosis report 2023. 2023.
2. 毛敏杰, 汪彩紅, 潘蕾. 細胞免疫和體液免疫功能檢測對重癥結核病患者的臨床意義. 中華危重癥醫學雜志(電子版), 2015, 8(2): 109-111.
3. Duro RP, Figueiredo Dias P, Ferreira AA, et al. Severe tuberculosis requiring intensive care: a descriptive analysis. Crit Care Res Pract, 2017, 2017: 9535463.
4. 劉同倫. 實用結核病學. 沈陽: 遼寧科學技術出版社, 1987: 284-289.
5. 蘇瑾文. 重癥肺結核學免疫特性研究. 北京: 中國人民解放軍醫學院, 2015.
6. Kim CW, Kim SH, Lee SN, et al. Risk factors related with mortality in patient with pulmonary tuberculosis. Tuberc Respir Dis (Seoul), 2012, 73(1): 38-47.
7. Loh WJ, Yu Y, Loo CM, et al. Factors associated with mortality among patients with active pulmonary tuberculosis requiring intensive care. Singapore Med J, 2017, 58(11): 656-659.
8. WHO. WHO handbook for guideline development (2nd ed). Vienna: World Health Organization, 2014.
9. Brouwers MC, Kho ME, Browman GP, et al. AGREE Ⅱ: advancing guideline development, reporting and evaluation in health care. CMAJ, 2010, 182(18): 839-842.
10. Chen Y, Yang K, Maru?ic A, et al. A reporting tool for practice guidelines in health care: the RIGHT statement. Ann Intern Med, 2017, 166(2): 128-132.
11. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 2017, 358: j4008.
12. Higgins JP, Altman DG, G?tzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 2011, 343: d5928.
13. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med, 2011, 155(8): 529-536.
14. Wells GA, Shea BJ, O'Connell D, et al. The Newcastle‐Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta‐analyses. 2011.
15. Moga C, Guo B, Schopflocher D, et al. Development of a quality appraisal tool for case series studies using a modified Delphi technique. 2012.
16. OCEBM Levels of Evidence Working Group. OCEBM levels of evidence. 2009.
17. 李純. 分析重癥肺結核合并呼吸衰竭的臨床特征. 中國醫藥指南, 2019, 17(24): 51.
18. 劉麗, 閆佩英. 重癥肺結核合并呼吸衰竭的臨床治療體會. 世界最新醫學信息文摘(連續型電子期刊), 2019, 19(38): 89-90.
19. 劉國波. 重癥肺結核合并呼吸衰竭的臨床護理. 中國醫藥指南, 2019, 17(1): 183-184.
20. 劉曉寧, 李曄. 青年重癥肺結核的臨床特點及其影響因素分析. 臨床肺科雜志, 2020, 25(9): 1419-1423.
21. 劉丹. 重癥肺結核合并呼吸衰竭的臨床護理. 飲食科學, 2017, (20): 1.
22. 蘇瑾文, 劉艷華, 楊秉芬, 等. 重癥繼發性肺結核患者差異表達基因和IL-1β表達的驗證. 中華臨床醫師雜志(電子版), 2014, (23): 4186-4190.
23. 蘇瑾文, 劉艷華, 楊秉芬, 等. CCL3、CCL4下調表達和重癥繼發性肺結核病理損傷的關系. 山西醫科大學學報, 2015, 46(4): 300-304.
24. 王譯, 陸利歡, 陳建. 重癥活動性肺結核患者凝血功能變化的臨床分析. 臨床醫藥文獻電子雜志, 2020, 7(13): 27-28.
25. 魯進, 黃漢平. 重癥肺結核病合并類白血病反應誤診分析報告1例. 中國醫藥科學, 2017, 7(18): 254-256.
26. 唐理斌, 李海雯. 經鼻高流量氧療與無創機械通氣在重癥肺結核合并呼吸衰竭中的療效對比研究. 健康必讀, 2019, (33): 23.
27. 戚世欽, 楊榮, 吳春玲. 含卷曲霉素化療方案聯合胸腺五肽和復方氨基酸雙肽治療重癥肺結核的臨床療效分析. 現代診斷與治療, 2016, 27(8): 1431-1433.
28. 國家衛生和計劃生育委員會. 肺結核診斷標準(WS 288-2017). 2017.
29. WHO. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: module 1: prevention. 2020.
30. 蔡靜, 汪求真, 韓秀霞, 等. 肺結核患者就診臨床表現及變化特點調查分析. 中華疾病控制雜志, 2012, 16(5): 417-420.
31. 李文君, 王玲, 曾令玉, 等. 72例涂陽肺結核患者臨床特點分析. 新疆醫學, 2018, 48(1): 47-50.
32. 張力英, 李琦, 王蘋, 等. 慢性阻塞性肺疾病合并肺性腦病的臨床特征及其危險因素分析. 中華肺部疾病雜志(電子版), 2021, 14(4): 530-532.
33. 中華醫學會呼吸病學分會. 中國成人社區獲得性肺炎診斷和治療指南(2016年版). 中華結核和呼吸雜志, 2016, 39(4): 253-279.
34. 張虹. 優質護理用于重癥結核合并糖尿病的臨床護理效果分析. 糖尿病新世界, 2018, 21(21): 131-132.
35. 陳娟, 毛毅, 陳洪德. 30例危重癥肺結核孕產婦的臨床特征及預后分析. 中國防癆雜志, 2020, 42(6): 638-640.
36. 劉燕俠. 肺結核合并肝性腦病34例護理體會. 中國實用神經疾病雜志, 2015, 18(13): 122.
37. 張亞敬, 姜影, 孫浩, 等. 154例老年肺結核患者的發現與治療轉歸情況分析. 結核與肺部疾病雜志, 2023, 4(1): 48-53.
38. 朱麗雅. 重癥肺結核合并呼吸衰竭的護理. 中國基層醫藥, 2013, 20(2): 296-297.
39. 謝朝云, 覃家露, 熊蕓, 等. 重癥肺結核患者死亡危險因素分析. 人民軍醫, 2018, 61(1): 30-33, 37.
40. 冀小波, 毛敏杰, 徐節坤, 等. 重癥肺結核合并真菌感染患者的臨床特征及發病危險因素分析. 浙江醫學, 2021, 43(18): 2013-2016, 2019.
41. 中華醫學會結核病學分會重癥專業委員會. 結核病營養治療專家共識. 中華結核和呼吸雜志, 2020, 43(1): 17-26.
42. 張楠, 李琦, 潘麗萍, 等. 結核重癥監護室真菌感染的危險因素分析. 中國醫藥導報, 2019, 16(1): 74-76, 81.
43. 王紅巖, 張昕. 結核重癥監護室呼吸機相關性肺炎感染的危險因素分析. 中國醫藥指南, 2020, 18(6): 108-109.
44. 王紅巖, 張昕. 重癥肺結核合并呼吸衰竭的臨床特征分析. 中國醫藥指南, 2020, 18(16): 130-131.
45. 萬青梅. 重癥肺結核合并呼吸衰竭患者的臨床護理方法以及效果評價. 醫學美學美容(中旬刊), 2014, 23(8): 366.
46. 疏欣楊, 唐亮, 孫兵. 呼吸重癥監護病房中以呼吸衰竭為突出表現的肺結核臨床特點. 中日友好醫院學報, 2014, 28(3): 139-142, 封2.
47. 石麗彩, 楊桂梅. 重癥肺結核合并呼吸衰竭患者的護理. 臨床合理用藥雜志, 2012, 5(29): 166.
48. 馬增光, 李志軍, 陳杰勇. 重癥肺結核79例臨床分析. 臨床合理用藥雜志, 2014, 7(25): 39.
49. 李先鋒. 青年重癥肺結核60例觀察與治療. 醫藥前沿, 2014, (8): 115-116.
50. 李紅. 重癥肺結核合并呼吸衰竭臨床分析. 中國衛生標準管理, 2015, 6(12): 132-133.
51. 李海濤, 郭曉新. 初治重癥肺結核發現延遲相關因素分析. 河南預防醫學雜志, 2012, 23(4): 275-276.
52. 龔惠莉. 60例重癥肺結核合并呼吸衰竭臨床分析. 現代預防醫學, 2012, 39(1): 248-249.
53. 劉巖, 丁龍. 30例重癥肺結核回顧性影像分析. 健康必讀旬刊, 2013, 12(11): 101.
54. Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med, 1995, 23(10): 1638-1652.
55. 中華醫學會結核病學分會. 肺結核診斷和治療指南. 中國實用鄉村醫生雜志, 2013, 20(2): 7-11.
56. Telisinghe L, Fielding KL, Malden JL, et al. High tuberculosis prevalence in a South African prison: the need for routine tuberculosis screening. PLoS One, 2014, 9(1): e87262.
57. Nguyen TBP, Nguyen TA, Luu BK, et al. A comparison of digital chest radiography and Xpert? MTB/RIF in active case finding for tuberculosis. Int J Tuberc Lung Dis, 2020, 24(9): 934-940.
58. 中華醫學會放射學分會傳染病放射學專業委員會. 肺結核影像學及分級診斷專家共識. 新發傳染病電子雜志, 2018, 3(2): 118-127.
59. 劉長春, 古海爾, 常銀勇, 等. 重癥肺結核CT影像分析. 臨床肺科雜志, 2007, 12(12): 1302-1304.
60. 陳影. 老年肺結核臨床分析. 中國實用醫藥, 2015, (15): 61-62.
61. 周偉劍. 艾滋病患者合并重癥肺結核的X線表現的探討. 現代醫用影像學, 2015, 24(6): 902-904.
62. 李寧, 王曉靜, 馮光, 等. 高能量營養乳劑的腸內營養對重癥肺結核機械通氣患者的臨床療效. 臨床肺科雜志, 2013, 18(5): 780-782.
63. Shaarawy H, El-Sayed Mohamed E. Assessment of the prevalence of pulmonary embolism in patients with severe pulmonary tuberculosis. Egypt J Chest Dis Tuberc, 2018, 67(1): 62-67.
64. 中華人民共和國國家衛生和計劃生育委員會. 結核病分類(WS196—2017). 新發傳染病電子雜志, 2018, 3(3): 191-192.
65. Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis, 2015, 211(Suppl 2): S21-S28.
66. 《中國防癆雜志》編輯委員會, 中國醫療保健國際交流促進會結核病防治分會基礎學組和臨床學組. 結核分枝桿菌耐藥性檢測專家共識. 中國防癆雜志, 2019, 41(2): 129-137.
67. 中華醫學會結核病學分會臨床檢驗專業委員會. 結核病病原學分子診斷專家共識. 中華結核和呼吸雜志, 2018, 41(9): 688-695.
68. 劉一典. 復治肺結核病診斷和治療專家共識. 中國防癆雜志, 2021, 43(12): 1226-1238.
69. Fusani L, Tersigni C, Chiappini E, et al. Old biomarkers in tuberculosis management: are they still useful. A systematic review. Expert Rev Anti Infect Ther, 2021, 19(10): 1191-1203.
70. Pierce R, Bigham MT, Giuliano JS. Use of procalcitonin for the prediction and treatment of acute bacterial infection in children. Curr Opin Pediatr, 2014, 26(3): 292-298.
71. Kamat IS, Ramachandran V, Eswaran H, et al. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis, 2020, 70(3): 538-542.
72. Martin-Loeches I, Torres A, Nagavci B, et al. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Eur Respir J, 2023, 61(4): 2200735.
73. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med, 2008, 177(5): 498-505.
74. 李成行, 李月翠. 檢測內毒素與C反應蛋白在診斷肺結核合并革蘭陰性菌感染中的意義. 中國防癆雜志, 2013, 35(9): 702-705.
75. 萬學紅, 盧雪峰. 診斷學(第9版). 北京: 人民衛生出版社, 2018: 409-442.
76. Jones BE, Oo MM, Taikwel EK, et al. CD4 cell counts in human immunodeficiency virus-negative patients with tuberculosis. Clin Infect Dis, 1997, 24(5): 988-991.
77. 俞朝賢, 李德憲, 王娟, 等. 結核重癥監護室患者外周血CD4+T淋巴細胞的檢測與臨床意義. 現代醫院, 2019, 19(7): 1084-1086.
78. 汪彩紅, 邱君克, 黃曉慶, 等. 重癥肺結核患者外周血T細胞亞群在預后不良患者中的表達及臨床意義. 中華醫院感染學雜志, 2020, 30(9): 1327-1330.
79. 衛芳征. 外周血T細胞亞群和紅細胞免疫功能與重癥肺結核患者不良預后的相關性. 臨床肺科雜志, 2018, 23(9): 1561-1565.
80. 黃健, 李明瑛, 牛文一, 等. 外周血Blimp1、IFN-γ、IL-10水平與重癥肺結核的相關性分析. 分子診斷與治療雜志, 2020, 12(12): 1745-1748.
81. 章敏. 外周血IFN-γ、IL-10水平及紅細胞免疫功能對重癥肺結核患者死亡預后的預測價值. 標記免疫分析與臨床, 2020, 27(7): 1161-1165.
82. Kho ME, McDonald E, Stratford PW, et al. Interrater reliability of APACHE Ⅱ scores for medical surgical intensive care patients: a prospect blinded study. Am J Crit Care, 2007, 16: 378-380.
83. Lambden S, Laterre PF, Levy MM, et al. The SOFA score-development, utility and challenges of accurate assessment in clinical trials. Crit Care, 2019, 23(1): 374.
84. 王超, 蘇強, 張淑文, 等. 多器官功能障礙綜合征病情嚴重度評分系統. 中國醫學科學院學報, 2007, 29(4): 497-500.
85. Wang D, Willis DR, Yih Y. The pneumonia severity index: assessment and comparison to popular machine learning classifiers. Int J Med Inform, 2022, 163: 104778.
86. 李寧, 王曉靜, 馮光, 等. 重癥肺結核合并COPD患者機械通氣死亡預后因素分析. 臨床肺科雜志, 2013, 18(4): 711-712.
87. Tatar D, Senol G, Kirakli C, et al. Contributing factors to mortality rates of pulmonary tuberculosis in intensive care units. J Chin Med Assoc, 2018, 81(7): 605-610.
88. Galvin J, Tiberi S, Akkerman O, et al. Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review. Pulmonology, 2022, 28(4): 297-309.
89. Rollas K, Kara A, Orta? Ersoy NE, et al. Acute tuberculosis in the intensive care unit. Turk J Med Sci, 2015, 45(4): 882-887.
90. 張如云, 張靜, 雷軒. 血清白蛋白、SOFA評分及APACHEⅡ評分對重癥肺結核患者預后的評估價值. 臨床肺科雜志, 2023, 28(3): 399-401,411.
91. Kim S, Kim H, Kim WJ, et al. Mortality and predictors in pulmonary tuberculosis with respiratory failure requiring mechanical ventilation. Int J Tuberc Lung Dis, 2016, 20(4): 524-529.
92. Cegielski JP, Arab L, Cornoni-Huntley J. Nutritional risk factors for tuberculosis among adults in the United States, 1971-1992. Am J Epidemiol, 2012, 176(5): 409-422.
93. WHO. WHO guidelines approved by the guidelines review committee. 2013.
94. Mueller C, Compher C, Ellen DM, et al. A. S. P. E. N. clinical guidelines: nutrition screening, assessment, and intervention in adults. JPEN J Parenter Enteral Nutr, 2011, 35(1): 16-24.
95. Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr, 2003, 22(3): 321-336.
96. Heyland DK, Dhaliwal R, Jiang X, et al. Identifying critically ill patients who benefit the most from nutrition therapy: the development and initial validation of a novel risk assessment tool. Crit Care, 2011, 15(6): R268.
97. 章志俊, 譚守勇. 營養風險篩查在結核病治療中應用. 中國防癆雜志, 2015, 37(9): 971-974.
98. 營養風險及營養支持調查協作組, 蔣朱明, 陳偉, 等. 中國東、中、西部大城市三甲醫院營養不良(不足)、營養風險發生率及營養支持應用狀況調查. 中國臨床營養雜志, 2008, 16(6): 335-337.
99. 顧良軍, 詹斯·康卓普, 雷米·梅耶, 等. 營養風險篩查2002改善臨床結局. 中華臨床營養雜志, 2013, 21(3): 133-139.
100. Felder S, Lechtenboehmer C, Bally M, et al. Association of nutritional risk and adverse medical outcomes across different medical inpatient populations. Nutrition, 2015, 31(11-12): 1385-1393.
101. Mukhopadhyay A, Henry J, Ong V, et al. Association of modified NUTRIC score with 28-day mortality in critically ill patients. Clin Nutr, 2017, 36(4): 1143-1148.
102. Canales C, Elsayes A, Yeh DD, et al. Nutrition risk in critically ill versus the nutritional risk screening 2002: are they comparable for assessing risk of malnutrition in critically ill patients. JPEN J Parenter Enteral Nutr, 2019, 43(1): 81-87.
103. Heyland DK, Dhaliwal R, Wang M, et al. The prevalence of iatrogenic underfeeding in the nutritionally 'at-risk' critically ill patient: results of an international, multicenter, prospective study. Clin Nutr, 2015, 34(4): 659-666.
104. 陳志, 梁建琴. 結核病重癥患者營養評估及營養支持治療專家共識. 中國防癆雜志, 2022, 44(5): 421-432.

Next Article
Comparative effectiveness research of Chinese medicine and integrated Chinese medicine and antimicrobial drugs in the treatment of pneumonia: a retrospective cohort study design

Chinese Journal of Evidence-Based Medicine

Guidelines for definition and diagnosis of severe pulmonary tuberculosis in adults in China (2023)

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content